Le Lézard
Classified in: Health, Business, Covid-19 virus
Subject: CXP

Comar to Expand East Coast Footprint


VOORHEES, N.J., June 3, 2020 /PRNewswire/ -- Comar, a premier healthcare plastic packaging, device and component supplier, is pleased to announce a major capacity expansion of our Buena plant operations by building a new offsite location in Vineland, New Jersey. 

Amid the considerable challenges brought on by COVID-19, we are very pleased to share this good news. The new 159,000 sq.ft. facility in Vineland, NJ, only a 20 minute drive from the current facility, will be ISO 13485 certified, cGMP compliant, FDA registered, and house injection molding and assembly and finishing machines, with additional capacity to support long-term growth. The expansion, which is scheduled to be completed by March 2021, will also enable us to refresh our Buena facility and increase capacity to better serve our customers.

Mike Ruggieri, CEO at Comar, said, "This investment builds on our new West Coast facility ? Rancho 2.0 ? and represents another exciting milestone for our organization. Our Buena plant has provided the engine for much of our growth over the decades. This next critical step of adding footprint, infrastructure, and capacity, will ensure that we continue to delight our customers and drive our growth moving forward."

Our Buena expansion effort will result in a range of benefits, including:

Linda Kershner, Buena Plant Manager at Comar, said "In addition to better serving our customers by bringing additional production capacity, the expansion in Southern New Jersey will create a better experience for our employees who are central to delighting our customers. I am extremely excited about both our current Buena and new Vineland facilities. The new Vineland location allows us to create a best-in-class  GMP compliant work environment right from the start and at the same time gives us  the opportunity to  refresh and optimize our Buena site."

Comar, headquartered in Voorhees, NJ, hosts nine strategic manufacturing and distribution locations and employs a host of rigid plastic packaging technologies including injection molding, injection blow molding, injection stretch blow molding, and extrusion blow molding which are complemented by a full suite of value-added service offerings. Comar is majority owned by Morgan Stanley Capital Partners.

Morgan Stanley Capital Partners, part of Morgan Stanley Investment Management, is a leading middle-market private equity firm that has invested capital in a broad spectrum of industries for over two decades, focused primarily on investing in North American based companies. They seek to create value by directly investing and partnering with middle-market, founder/family-managed companies to accelerate their growth initiatives.

 

SOURCE Comar


These press releases may also interest you

at 06:30
Boston Scientific Corporation generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior...

at 06:28
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Pharma Parenteral Packaging Market ? By Drug Type (Small Molecules, Biologics, Vaccines, Biosimilars, & Others), By Product Type (Bottles, Ampoules,...

at 06:15
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points...

at 06:10
Thermo Fisher Scientific Inc. , the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City. The format will feature presentations by members of Thermo Fisher...

at 06:05
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP...

at 06:05
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's...



News published on and distributed by: